微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 27.66% | 10.54% | -6.39% | 33/159 | 44.41% | 诺诚健华 | 91.19% | 行业排名> |
| 2026-06-30 | 29.55% | 14.83% | 0.83% | 115/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 29.3% | 22.02% | 11.18% | 113/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 26.36% | 10.53% | 5.33% | 125/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 25.02% | 3.27% | -2.75% | 127/159 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 25.73% | 4.18% | 7.14% | 128/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 24.02% | -0.12% | 0.71% | 125/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 23.85% | -7.09% | -1.59% | 132/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 24.23% | -9.52% | -1.9% | 128/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 24.7% | -7.14% | 2.72% | 130/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 24.04% | -14% | -6.31% | 128/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 25.66% | 7.36% | -4.17% | 130/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 26.78% | 8.99% | 0.68% | 124/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 26.6% | 5.25% | -4.87% | 126/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 27.96% | 3.74% | 16.96% | 121/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 23.9% | -10.57% | -2.71% | 134/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 24.57% | -14.27% | -2.78% | 126/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 25.27% | -16.8% | -6.23% | 130/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 26.95% | -10.58% | 0.83% | 118/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 26.73% | -4.39% | -6.73% | 132/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 28.66% | 1.56% | -5.65% | 116/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 30.38% | 7.76% | 0.78% | 121/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 30.14% | 4.37% | 7.8% | 104/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 27.96% | -13.63% | -0.92% | 128/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 28.22% | -11.86% | 0.11% | 106/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 28.19% | -12.23% | -2.39% | 115/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 28.88% | -8.78% | -10.79% | 96/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 32.37% | 1.38% | 1.1% | 113/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 32.02% | 6.63% | -0.31% | 91/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 32.12% | 7.58% | 1.45% | 97/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 31.66% | 4.28% | -0.86% | 90/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 31.93% | 3.55% | 6.34% | 110/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 30.03% | 5.8% | 0.59% | 86/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 29.85% | 8.98% | -1.66% | 91/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 30.36% | 16.68% | -1.55% | 85/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 30.84% | 10.82% | 8.65% | 97/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 28.38% | 9.65% | 3.6% | 80/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 27.39% | 3.52% | 5.29% | 84/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 26.02% | -2.25% | -6.5% | 75/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 27.83% | 1.59% | 7.51% | 93/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 25.88% | -1.5% | -2.2% | 67/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 26.46% | 3.96% | -0.57% | 74/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 26.61% | 10.81% | -2.84% | 63/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |